Show simple item record

AuthorLemanska, Agnieszka
AuthorPoole, Karen
AuthorManders, Ralph
AuthorMarshall, John
AuthorNazar, Zachariah
AuthorNoble, Kevin
AuthorSaxton, John M.
AuthorTurner, Lauren
AuthorWarner, Gary
AuthorGriffin, Bruce A.
AuthorFaithfull, Sara
Available date2021-08-19T08:12:24Z
Publication Date2021-07-21
Publication NameSupportive Care in Cancer
Identifierhttp://dx.doi.org/10.1007/s00520-021-06404-5
CitationLemanska, A., Poole, K., Manders, R. et al. Patient activation and patient-reported outcomes of men from a community pharmacy lifestyle intervention after prostate cancer treatment. Support Care Cancer (2021). https://doi.org/10.1007/s00520-021-06404-5
ISSN09414355
URIhttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85110878817&origin=inward
URIhttp://hdl.handle.net/10576/22077
AbstractPurpose: To report patient activation, which is the knowledge, skills, and confidence in self-managing health conditions, and patient-reported outcomes of men after prostate cancer treatment from a community pharmacy lifestyle intervention. Methods: The 3-month lifestyle intervention was delivered to 116 men in nine community pharmacies in the UK. Patient Activation Measure (PAM) was assessed at baseline, 3 and 6 months. Prostate cancer-related function and quality of life were assessed using the European Prostate Cancer Index Composite (EPIC-26) and EuroQOL 5-dimension 5-level (EQ5D-5L) questionnaires at baseline and 6 months. Lifestyle assessments included Mediterranean Diet Adherence Screener (MEDAS) at baseline, 3 and 6 months and Godin Leisure Time Exercise Questionnaire (GLTEQ) at baseline and 3 months. Results: PAM score increased from 62 [95% CI 59–65] at baseline to 66 [64–69] after the intervention (p = 0.001) and remained higher at 6 months (p = 0.008). Scores for all the EPIC-26 domains (urinary, bowel and hormonal) were high at both assessments, indicating good function (between 74 [70–78] and 89 [86–91]), except sexual domain, where scores were much lower (21 [17–25] at baseline, increasing to 24 [20–28] at 6 months (p = 0.012)). In EQ5D-5L, 3% of men [1–9] reported self-care problems, while 50% [41–60] reported pain and discomfort, and no significant changes over time. Men who received androgen deprivation therapy, compared with those who did not, reported higher (better) urinary incontinence scores (p < 0.001), but lower (worse) scores in the urinary irritative/obstructive (p = 0.003), bowel (p < 0.001) and hormonal (p < 0.001) domains. Poor sexual function was common across all age groups irrespective of prostate cancer treatment. Conclusions: The intervention led to significant improvements in patient activation, exercise and diet. Community pharmacy could deliver effective services to address sexual dysfunction, pain and discomfort which are common after prostate cancer.
Languageen
PublisherSpringer
SubjectCommunity pharmacy
Lifestyle interventions
Patient-reported outcomes (PROs)
Prostate cancer
TitlePatient activation and patient-reported outcomes of men from a community pharmacy lifestyle intervention after prostate cancer treatment
TypeArticle
dc.accessType Open Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record